Bond Biosciences

Bond Biosciences is an early-stage biotech developing non-absorbed oral polymers to sequester excess dietary ions in the GI tract, preventing systemic absorption and related diseases. Its lead candidate, BBI-001, targets Hereditary Hemochromatosis, a genetic iron overload disorder with no FDA-approved pharmacologic therapy, positioning it to address a significant unmet need. The company, founded in 2021, is led by a team with strong backgrounds in drug development, corporate strategy, and venture capital, and is backed by a seed round from its co-founders. Its platform technology holds potential for expansion into other ion-related disorders.

Platform for designing non-absorbed oral polymers that selectively bind excess dietary metal ions in the gastrointestinal tract to prevent systemic absorption and disease.

In Hereditary Hemochromatosis, Bond faces no direct pharmacologic competition, as the standard of care is invasive phlebotomy. Its main competition is the entrenched medical practice, not another drug. For potential future indications like hyperphosphatemia, it would compete against established phosphate binder markets dominated by large pharma.